- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04446351
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
October 29, 2023 updated by: GlaxoSmithKline
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors.
In addition, dostarlimab will be given as monotherapy (Arm D); and in combination with belrestotug (Arm E); and with GSK6097608 + belrestotug (Arm F) in Japanese and Chinese participants.
The study may assess the PK/PD cohorts for Arm E and/or Arm F in participants outside of China and Japan.
Additionally, dostarlimab will be given in combination with cobolimab in Japanese participants.
Drug name mentioned as belrestotug, GSK4428859A and EOS884448 are interchangeable for the same compound.
In the rest of the document, the drug will be referred to as belrestotug.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
244
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
Study Contact Backup
- Name: EU GSK Clinical Trials Call Center
- Phone Number: +44 (0) 20 89904466
- Email: GSKClinicalSupportHD@gsk.com
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Scott A Laurie
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Toronto, Ontario, Canada, M5G 1Z5
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Lillian Siu
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Chiba, Japan, 277-8577
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Yoshitaka Zenke
-
Tokyo, Japan, 104-0045
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Noboru Yamamoto
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Dong-Wan Kim
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Seoul, Korea, Republic of, 06351
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Myung-Ju Ahn
-
-
-
-
California
-
Los Angeles, California, United States, 90025
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Omid Hamid
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Frank Stephen Hodi
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
Texas
-
Dallas, Texas, United States, 75230
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Reva Elaine Schneider
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Houston, Texas, United States, 77030-4009
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Jordi Rodon Ahnert
-
San Antonio, Texas, United States, 78229
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Drew W Rasco
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adults 18 years of age or older (or >=20 years of age in Arm-A Japan, Arm-D Japan, Arm E-Japan, Arm F-Japan, and Arm G-Japan)
- Female participants of childbearing potential must agree to use a highly effective form of contraception
- Histological or cytological documentation of locally advanced, recurrent, or metastatic solid malignancy. Enrollment in PK/PD cohorts will be restricted to participants with histologically or cytologically confirmed diagnosis of 1 or more of the following: non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), endometrial cancer (EC), colorectal cancer (CRC) (including specified molecular subtypes of these) or an alternative immunogenic tumor type with medical monitor approval
- Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists
- Participants in a PK/PD cohort (Arms A, B, E and F) must provide fresh tumor biopsies. Biopsies are not required from participants enrolled in Arm D, Arm E, (non-PK/PD cohorts only), Arm F (non-PK/PD cohort only), Arm G or any participant enrolled in mainland China
- Eastern cooperative oncology group (ECOG) performance status (PS) 0 to 1
- Life expectancy of at least 12 weeks
- Adequate organ function as determined by laboratory assessments
- Adequate cardiac ejection fraction as measured by echocardiogram
- Arm A-Japan, Arm D-Japan, Arm E-Japan, Arm F-Japan, and Arm G-Japan only: lives in Japan and is racially Japanese, defined as all biological grandparents being Japanese
- Arm A-China, Arm B-China, Arm D-China, Arm E-China and Arm F-China only (excluding PK/PD cohorts in Arm E and Arm F): is of Chinese descent and lives in China
- Arm D, Arm E, Arm F, and Arm G only: has been deemed suitable for assigned treatment based on assessment by the investigator
Exclusion Criteria:
- Prior anti-cancer treatment including investigational agents, immune checkpoint inhibitors, chemotherapy, targeted therapy, and biological therapy: within 4 weeks or 5 half-lives of the drug, whichever is shorter
- Prior allogenic or autologous bone marrow transplantation or other solid organ transplantation
- Toxicity from previous anticancer treatment, including; greater than or equal to (>=) Grade 3 immune-mediated toxicity considered related to prior immunotherapy and that led to treatment discontinuation; or toxicity related to prior treatment that has not resolved; or history of myocarditis of any grade during a previous treatment with immunotherapy
- Known additional malignancy that progressed or required active treatment within the last 2 years
- Uncontrolled or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years
- Concurrent medical condition requiring the use of systemic immunosuppressive treatment
- Cirrhosis or current unstable liver or biliary disease per investigator assessment
- Active infection requiring systemic treatment, known human immunodeficiency virus infection, or positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)
- Prolonged QT as measured by electrocardiogram
- Allergen desensitization therapy within 4 weeks of starting study intervention
- History of hypersensitivity to any of the study interventions or their excipients
- Has a history or evidence of cardiac abnormalities within the 6 months prior to enrolment
- Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions
- History of idiopathic pulmonary fibrosis; interstitial lung disease; organizing pneumonia; noninfectious pneumonitis that required steroids, or evidence of active, noninfectious pneumonitis
- Pregnant or lactating woman
- Receipt of live vaccine within 30 days of the start of study intervention
- Receipt of transfusion of blood products or administration of colony-stimulating factors within 14 days before the first dose of study intervention
- Major surgery less than 4 weeks before the first dose of study intervention
- Known drug or alcohol abuse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants receiving GSK6097608 monotherapy (Arm A)
Participants will be administered an intravenous (IV) infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses.
|
GSK6097608 will be administered as an IV infusion.
|
Experimental: Participants receiving GSK6097608 plus dostarlimab (Arm B)
Participants will be administered IV infusion of GSK6097608 every 3 weeks in escalating doses followed by dostarlimab.
|
GSK6097608 will be administered as an IV infusion.
Dostarlimab will be administered as an IV infusion.
|
Experimental: Participants receiving dostarlimab monotherapy (Arm D)
Participants will be administered an IV infusion of dostarlimab monotherapy (1 cohort will receive dostarlimab every 3 weeks and 1 cohort will receive dostarlimab every 6 weeks).
|
Dostarlimab will be administered as an IV infusion.
|
Experimental: Participants receiving dostarlimab plus cobolimab (Arm G)
Participants will be administered an IV infusion of cobolimab followed by dostarlimab
|
Dostarlimab will be administered as an IV infusion.
Cobolimab will be administered as an IV infusion.
|
Experimental: Participants receiving dostarlimab plus belrestotug (Arm E)
Participants will be administered IV infusions of dostarlimab followed by belrestotug, every 3 weeks.
|
Dostarlimab will be administered as an IV infusion.
Belrestotug will be administered as an IV infusion.
Other Names:
|
Experimental: Participants receiving dostarlimab plus belrestotug plus GSK6097608 (Arm F)
Participants will be administered an IV infusion of dostarlimab followed by belrestotug followed by GSK6097608 every 3 weeks.
|
GSK6097608 will be administered as an IV infusion.
Dostarlimab will be administered as an IV infusion.
Belrestotug will be administered as an IV infusion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with dose-limiting toxicities (DLTs)
Time Frame: Up to Day 21
|
Up to Day 21
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Up to 2 years
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with clinically significant changes in laboratory parameters, vital signs, and 12-lead electrocardiogram (ECG) findings
Time Frame: Up to 2 years
|
Up to 2 years
|
Number of participants with dose reductions or delay
Time Frame: Up to 2 years
|
Up to 2 years
|
Number of participants withdrawn due to AEs
Time Frame: Up to 2 years
|
Up to 2 years
|
Overall response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms A, B, F: Number of participants with positive anti-drug antibodies (ADAs) against GSK6097608
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms A, B, F: Titers of ADAs against GSK6097608
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms A, B, F: Maximum observed concentration (Cmax) for GSK6097608
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms A, B, F: Minimum observed concentration (Cmin) for GSK6097608
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms A, B, F: Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC[0-infinity]) for GSK6097608
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms A, B, F: Area under the plasma concentration-time curve from time zero to time (AUC[0-t]) for GSK6097608
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms A, B, F: Apparent terminal phase half-life (t1/2) for GSK6097608
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms D, E, F, G: ORR based on modified Response Evaluation Criteria in Solid Tumors (iRECIST)
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms D, E, F, G: Disease Control Rate (DCR) based on RECIST 1.1
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms D, E, F, G: DCR based on iRECIST
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms D, E, F, G: Time to response (TTR) based on RECIST 1.1
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms D, E, F, G: TTR based on iRECIST
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms D, E, F, G: Duration of response (DOR) based on RECIST 1.1
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms D, E, F, G: DOR based on iRECIST
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms D, E, F, G: Progression-free survival (PFS) based on RECIST 1.1
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms D, E, F, G: PFS based on iRECIST
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms B, D, E, F, G: Number of participants with positive ADAs against dostarlimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms B, D, E, F, G: Titers of ADAs against dostarlimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arm G: Number of participants with positive ADAs against cobolimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arm G: Titers of ADAs against cobolimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms B, D, E, F, G: Cmax for dostarlimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms B, D, E, F, G: Cmin for dostarlimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms B, D, E, F, G: AUC(0-infinity) for dostarlimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms B, D, E, F, G: AUC(0-t) for dostarlimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms B, D, E, F, G: t1/2 for dostarlimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arm G: Cmax for cobolimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arm G: Cmin for cobolimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arm G: AUC(0-infinity) for cobolimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arm G: AUC(0-t) for cobolimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arm G: t1/2 for cobolimab
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms E, F: Number of participants with positive ADAs against belrestotug
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms E, F: Titers of ADAs against belrestotug
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms E, F: Cmax for belrestotug
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms E, F: Cmin for belrestotug
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms E, F: AUC(0-infinity) for belrestotug
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms E, F: AUC(0-t) for belrestotug
Time Frame: Up to 2 years
|
Up to 2 years
|
Arms E, F: t1/2 for belrestotug
Time Frame: Up to 2 years
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 25, 2020
Primary Completion (Estimated)
September 3, 2025
Study Completion (Estimated)
September 3, 2025
Study Registration Dates
First Submitted
June 22, 2020
First Submitted That Met QC Criteria
June 22, 2020
First Posted (Actual)
June 24, 2020
Study Record Updates
Last Update Posted (Actual)
October 31, 2023
Last Update Submitted That Met QC Criteria
October 29, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 212214
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal.
Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD Sharing Time Frame
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications
IPD Sharing Access Criteria
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
European Association for Endoscopic SurgeryWithdrawn
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Moscow Clinical Scientific CenterRecruitingCecal Neoplasms | Colonic Neoplasms MalignantRussian Federation
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on GSK6097608
-
GlaxoSmithKlineiTeos TherapeuticsRecruitingNeoplasms, Head and NeckUnited States, Italy, Spain, Taiwan, Germany, Greece, Korea, Republic of, Romania, Sweden, Turkey, Canada, Argentina, Finland, Brazil, Japan, Poland, Portugal, France, Denmark, Hungary, Norway
-
GlaxoSmithKlineiTeos TherapeuticsRecruitingLung Cancer, Non-Small CellFinland, Italy, Netherlands, Spain, United States, Argentina, Belgium, Brazil, Germany, Greece, Hungary, Korea, Republic of, United Kingdom, Poland, France, Thailand, Japan, South Africa, Turkey, United Arab Emirates, Mexico, Port...
-
GlaxoSmithKlineiTeos Belgium SARecruitingNeoplasmsUnited States, Italy, Spain, France, Germany, Canada, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Sweden